Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 66 results for diabetic foot

  1. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

  2. What is the clinical effectiveness of different dressing types in treating diabetic foot problems?

    is the clinical effectiveness of different dressing types in treating diabetic foot problems? Any explanatory notes(if applicable) Source

  3. What is the clinical effectiveness of maggot debridement therapy in the debridement of diabetic foot ulcers?

    clinical effectiveness of maggot debridement therapy in the debridement of diabetic foot ulcers? Any explanatory notes(if applicable)...

  4. What is the role of educational models and psycho-behavioural interventions in prevention of diabetic foot complications?

    educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...

  5. What is the clinical effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers?

    effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers? Any explanatory notes(if applicable) Source

  6. Education and psycho-behavioural interventions for prevention:- What is the role of educational models and psycho-behavioural interventions in prevention of diabetic foot complications?

    educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...

  7. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  8. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  9. Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the disease and is such monitoring cost effective?

    NG19/1 Question Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the...

  10. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  11. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  12. LQD Spray for treating acute and chronic wounds (MIB202)

    NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .

  13. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .

  14. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

    Topic prioritisation

  15. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .